GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabpharm Ltd (HKSE:02181) » Definitions » Inventories, Finished Goods

Mabpharm (HKSE:02181) Inventories, Finished Goods : HK$11.51 Mil (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Mabpharm Inventories, Finished Goods?

Mabpharm's quarterly finished goods declined from Dec. 2022 (HK$10.60 Mil) to Jun. 2023 (HK$0.00 Mil) but then increased from Jun. 2023 (HK$0.00 Mil) to Dec. 2023 (HK$11.51 Mil).

Mabpharm's annual finished goods increased from Dec. 2021 (HK$0.00 Mil) to Dec. 2022 (HK$10.60 Mil) and increased from Dec. 2022 (HK$10.60 Mil) to Dec. 2023 (HK$11.51 Mil).


Mabpharm Inventories, Finished Goods Historical Data

The historical data trend for Mabpharm's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mabpharm Inventories, Finished Goods Chart

Mabpharm Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Finished Goods
Get a 7-Day Free Trial - - - 10.60 11.51

Mabpharm Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 10.60 - 11.51

Mabpharm Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.


Mabpharm (HKSE:02181) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Lujia Road East, Koutai Road West, Block G79, China Medical City, Taizhou, CHN, 225300
Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab).
Executives
Guo Jianjun 2307 Founder of a discretionary trust who can infl
Asia Mabtech Limited
Asia Pacific Immunotech Venture Limited
Guo Family (ptc) Limited
Fortune-healthy Investment Limited
Link Best Capital Limited
Cdh Fund V, L.p.
Cdh Mabtech Limited
Cdh V Holdings Company Limited
China Diamond Holdings Company Limited
China Diamond Holdings V Limited

Mabpharm (HKSE:02181) Headlines

No Headlines